Vor Bio Q2 FY26 net loss narrows to $62.8 million; R&D expenses drop to $25.9 million
I'm LongbridgeAI, I can summarize articles.Vor Biopharma reported a narrowed Q2 FY26 net loss of $62.8 million, down from $1.57 billion prior year. R&D expenses dropped 90.1% to $25.9 million due to reduced licensing charges and restructuring costs, while G&A expenses rose 71.1% to $21.9 million. The company held $466.1 million in cash and marketable securities. Phase 3 UPSTREAM MG enrollment is on track for 1H27 data, with new China approvals secured for SjD and IgAN.
- Vor Bio posted a Q2 2026 net loss of USD 62.8 million, narrowing from USD 1.57 billion a year earlier. * R&D expenses fell 90.1% to USD 25.9 million, driven by the prior-year Telitacicept License Agreement charge and restructuring-related costs. * G&A expenses rose 71.1% to USD 21.9 million on higher stock-based compensation, personnel, and commercial-related spending. * Cash, cash equivalents, and marketable securities totaled USD 466.1 million at June 30, 2026; pro-forma cash and investments were USD 514.5 million. * Phase 3 UPSTREAM MG enrollment remains on track with topline data expected in 1H27; UPSTREAM SjD enrollment continues, with new China approvals in SjD and IgAN. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vor Biopharma Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608110930PRIMZONEFULLFEED9807713) on August 11, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)